BACKGROUND: Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in human endometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers. PATIENTS AND METHODS: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome. RESULTS: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P < 0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS. CONCLUSIONS: Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.
BACKGROUND:Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in humanendometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers. PATIENTS AND METHODS: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome. RESULTS: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P < 0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS. CONCLUSIONS:Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.
Authors: Israel Zighelboim; Andrew J Reinhart; Feng Gao; Amy P Schmidt; David G Mutch; Premal H Thaker; Paul J Goodfellow Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Miranda P Ween; Katja Hummitzsch; Raymond J Rodgers; Martin K Oehler; Carmela Ricciardelli Journal: Clin Exp Metastasis Date: 2010-12-12 Impact factor: 5.150
Authors: Clelia Domenzain-Reyna; Daniel Hernández; Laia Miquel-Serra; María José Docampo; Celia Badenas; Angels Fabra; Anna Bassols Journal: J Biol Chem Date: 2009-03-06 Impact factor: 5.157